Suchergebnisse - "Frisell, Thomas"

PubPharm (6)

1

Risk of depression in multiple sclerosis across disease-modifying therapies

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Longinetti, E. | Frisell, T. | Englund, S. | +3

2

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2020

von Granqvist, M. | Burman, J. | Gunnarsson, M. | +8

3

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

enthalten in: Annals of neurology | 2020

von Alping, P. | Askling, J. | Burman, J. | +13

4

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

enthalten in: JAMA neurology | 2020

von Luna, G. | Alping, P. | Burman, J. | +13

CommentIn: J Neurol. 2020 May;267(5):1567-1569. - PMID 32303837

5

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

enthalten in: JAMA neurology | 2018

von Granqvist, M. | Boremalm, M. | Poorghobad, A. | +4

6

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

enthalten in: Annals of neurology | 2016

von Alping, P. | Frisell, T. | Novakova, L. | +9

CommentIn: Ann Neurol. 2016 Nov;80(5):791-792. - PMID 27553863

1
[1]